Comparison of three different treatment modalities in the management of cancer cachexia

Simple item page
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorÇubukçu, Erdem
dc.contributor.buuauthorAvcı, Nilüfer
dc.contributor.buuauthorBudak, Ferah Ah
dc.contributor.buuauthorErcan, İlker
dc.contributor.buuauthorCanhoroz, Mustafa
dc.contributor.buuauthorÖlmez, Fatih
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.contributor.scopusid53986153800tr_TR
dc.contributor.scopusid55390409800tr_TR
dc.contributor.scopusid6701913697tr_TR
dc.contributor.scopusid6603789069tr_TR
dc.contributor.scopusid52663246200tr_TR
dc.contributor.scopusid57225252501tr_TR
dc.date.accessioned2022-12-05T06:59:40Z
dc.date.available2022-12-05T06:59:40Z
dc.date.issued2013
dc.description.abstractAims and background. The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia. Methods. Sixty-two assessable cachectic cancer patients were randomized to one of the following three arms: 1) megesterol acetate (MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral EPA-enriched nutritional supplement (n = 18). Treatment duration was 3 months. Results. The treatment arms were well balanced at baseline. The primary efficacy (body weight and lean body mass) and secondary efficacy (body mass index, quality of life, and serum levels of IL-6 and TNF-alpha) parameters improved after treatment in all three arms. There were no statistically significant differences between treatment groups in the mean percentage changes in all efficacy parameters from baseline to end of study. Conclusions. MA plus meloxicam or EPA supplement plus meloxicam may be effective treatment options in the management of cancer cachexia. The combined use of these agents does not provide further advantages.en_US
dc.identifier.citationKanat, O. vd. (2013). ''Comparison of three different treatment modalities in the management of cancer cachexia''. Tumori Journal, 99(2), 229-233.en_US
dc.identifier.endpage233tr_TR
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue2tr_TR
dc.identifier.pubmed23748819tr_TR
dc.identifier.scopus2-s2.0-84881227568tr_TR
dc.identifier.startpage229tr_TR
dc.identifier.urihttps://doi.org/10.1177/030089161309900218
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/030089161309900218
dc.identifier.urihttp://hdl.handle.net/11452/29659
dc.identifier.volume99tr_TR
dc.identifier.wos000322748000018tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSage Publicationsen_US
dc.relation.journalTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectCanceren_US
dc.subjectCachexiaen_US
dc.subjectMegesterol acetateen_US
dc.subjectMeloxicamen_US
dc.subjectEicosapentaenoic aciden_US
dc.subjectIII Clinical-trialen_US
dc.subjectMegestrol-acetateen_US
dc.subjectDouble-blinden_US
dc.subjectAnorexiaen_US
dc.subjectCelecoxiben_US
dc.subjectTherapyen_US
dc.subjectCyclooxygenase-2en_US
dc.subjectChemotherapyen_US
dc.subject.emtreeIcosapentaenoic aciden_US
dc.subject.emtreeInterleukin 6en_US
dc.subject.emtreeMegestrol acetateen_US
dc.subject.emtreeMeloxicamen_US
dc.subject.emtreeProsureen_US
dc.subject.emtreeTumor necrosis factor alphaen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeAppetite stimulanten_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeIcosapentaenoic aciden_US
dc.subject.emtreeInterleukin 6en_US
dc.subject.emtreeMegestrol acetateen_US
dc.subject.emtreeMeloxicamen_US
dc.subject.emtreeThiazine derivativeen_US
dc.subject.emtreeProstaglandin synthase inhibitoren_US
dc.subject.emtreeTumor necrosis factor alphaen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeBody weighten_US
dc.subject.emtreeCachexiaen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiet supplementationen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLean body weighten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePatient careen_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeTherapy effecten_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeCachexiaen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeNeoplasmen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeVery elderlyen_US
dc.subject.emtreeWeight gainen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAppetite stimulantsen_US
dc.subject.meshBiological markersen_US
dc.subject.meshBody mass indexen_US
dc.subject.meshCachexiaen_US
dc.subject.meshCyclooxygenase inhibitorsen_US
dc.subject.meshEicosapentaenoic aciden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInterleukin-6en_US
dc.subject.meshMaleen_US
dc.subject.meshMegestrol acetateen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshQuality of lifeen_US
dc.subject.meshNeoplasmsen_US
dc.subject.meshThiazinesen_US
dc.subject.meshThiazolesen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTumor necrosis factor-alphaen_US
dc.subject.meshWeight gainen_US
dc.subject.scopusCachexia; Skeletal Muscle; Muscle Atrophyen_US
dc.subject.wosOncologyen_US
dc.titleComparison of three different treatment modalities in the management of cancer cachexiaen_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus